Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
To compare the safety and tolerability of temsirolimus and sorafenib when used as single agents in the second-line setting in subjects with advanced RCC who have failed prior first-line treatment with sunitinib due to progressive disease (PD). To compare the efficacy, as measured by PFS (determined by a centralized independent assessment), of temsirolimus and sorafenib when used as single agents in the second-line setting in subjects with advanced RCC who have failed prior first-line treatment with sunitinib.
Inclusion criteria
- Patients With Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib Therapy